{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:34:01Z","timestamp":1785900841122,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115861","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:41:03Z","timestamp":1699623663000},"page":"115861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comprehensive UHPLC\u2013MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation"],"prefix":"10.1016","volume":"238","author":[{"given":"Jakub","family":"Jire\u0161","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Dou\u0161a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Gibala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Doubsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u011b\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mervart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardita","family":"Veseli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Kal\u00e1\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"\u0158ezanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jpba.2023.115861_bib1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/0091270006289850","article-title":"Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects","volume":"46","author":"Herman","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.jpba.2023.115861_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1039\/B701677H","article-title":"Amide bond formation: beyond the myth of coupling reagents","volume":"38","author":"Valeur","year":"2009","journal-title":"Chem. Soc. Rev."},{"issue":"8","key":"10.1016\/j.jpba.2023.115861_bib3","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1039\/D0RA10273C","article-title":"Two methods for the preparation of sitagliptin phosphate via chemical resolution and asymmetric hydrogenation","volume":"11","author":"Ye","year":"2021","journal-title":"RSC Adv."},{"issue":"18","key":"10.1016\/j.jpba.2023.115861_bib4","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1055\/s-0033-1340079","article-title":"Catalytic enantioselective allylic amination of olefins for the synthesis of ent-sitagliptin","volume":"24","author":"Bao","year":"2013","journal-title":"Synlett"},{"issue":"25","key":"10.1016\/j.jpba.2023.115861_bib5","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1021\/ja902462q","article-title":"Highly efficient asymmetric synthesis of sitagliptin","volume":"131","author":"Hansen","year":"2009","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.jpba.2023.115861_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/156802607780091028","article-title":"Discovery of JANUVIA\u2122 (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of Type2 diabetes","volume":"7","author":"Thornberry","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"10.1016\/j.jpba.2023.115861_bib9","first-page":"3494","article-title":"Isolation, characterization of degradation products of sitagliptin and development of validated stability-indicating HPLC assay method for sitagliptin API and tablets","volume":"4","author":"Dnyaneshwar","year":"2013","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.jpba.2023.115861_bib10","doi-asserted-by":"crossref","unstructured":"N. Vuyyuru, G. Krishna Ph.D, B. Ramadevi, Y. Kumar, Evaluation of Process Impurities and Degradants of Sitagliptin Phosphate by Validated Stability Indicating RP-LC Method, Asian Journal of Chemistry 29(9) (2017) 1941\u20131947, https:\/\/doi.org\/10.14233\/ajchem.2017.20632.","DOI":"10.14233\/ajchem.2017.20632"},{"issue":"10","key":"10.1016\/j.jpba.2023.115861_bib11","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/slct.201702552","article-title":"Efficient and convenient synthetic routes for sitagliptin impurities","volume":"3","author":"Metil","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.jpba.2023.115861_bib12","unstructured":"WHO Information Note: Update on Nitrosamine Impurities, 2019. \u3008https:\/\/www.who.int\/news\/item\/20\u201311-2019-information-note-nitrosamine-impurities\u3009. (Accessed 25. 9. 2023)."},{"key":"10.1016\/j.jpba.2023.115861_bib13","article-title":"Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine","volume":"51","author":"Peto","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2023.115861_bib14","article-title":"Estimated cancer risks associated with nitrosamine contamination in commonly used medications","author":"Li","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.jpba.2023.115861_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104749","article-title":"Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data","volume":"116","author":"Thresher","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115861_bib16","unstructured":"FDA Works to Avoid Shortage of Sitagliptin Following Detection of Nitrosamine Impurity, 2022. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-works-avoid-shortage-sitagliptin-following-detection-nitrosamine-impurity\u3009. (Accessed 23.02.2023)."},{"key":"10.1016\/j.jpba.2023.115861_bib17","unstructured":"Procedure under Article 5(3) of Regulation EC (No) 726\/2004, Nitrosamine impurities in human medicinal products, Procedure number: EMEA\/H\/A-5(3)\/149, 2020. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53\u20131490-assessment-report_en.pdf\u3009. (Accessed 5.9.2022)."},{"key":"10.1016\/j.jpba.2023.115861_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114300","article-title":"The determination of two analogues of 4-(azidomethyl)-1,1'-biphenyl as potential genotoxic impurities in the active pharmaceutical ingredient of several sartans containing a tetrazole group","volume":"205","author":"Jire\u0161","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115861_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113877","article-title":"Insight into the formation of N-nitrosodimethylamine in metformin products","volume":"195","author":"Jire\u0161","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.jpba.2023.115861_bib20","first-page":"119","article-title":"HILIC\u2013MS Determination of Genotoxic Impurity of 2-Chloro-N-(2-Chloroethyl)Ethanamine in the Vortioxetine Manufacturing Process","volume":"54","author":"Dou\u0161a","year":"2016","journal-title":"J. Chromatogr. Sci."},{"issue":"3","key":"10.1016\/j.jpba.2023.115861_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1039\/D2AY01821G","article-title":"A highly sensitive LC-MS\/MS method for the determination and quantification of a recently identified N-nitrosamine impurity in the sitagliptin phosphate monohydrate active pharmaceutical ingredient","volume":"15","author":"Wang","year":"2023","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jpba.2023.115861_bib22","unstructured":"International Council for Harmonization (ICH) Guideline: M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk, 2018. \u3008https:\/\/www.fda.gov\/media\/85885\/download\u3009. (Accessed 6. 4. 2020)."},{"key":"10.1016\/j.jpba.2023.115861_bib23","unstructured":"Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products. EMA\/409815\/2020 Rev.14. 21 December 2022., 2022. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53\u20131490-questions-answers-marketing-authorisation-holders\/applicants-chmp-opinion-article-53-regulation-ec-no-726\/2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf\u3009. (Accessed 10.01.2023)."},{"key":"10.1016\/j.jpba.2023.115861_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0022-2860(94)09016-I","article-title":"Rotational spectra of methyl ethyl and methyl propyl nitrosamines. Conformational assignment, internal rotation and quadrupole coupling","volume":"346","author":"Walker","year":"1995","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jpba.2023.115861_bib26","doi-asserted-by":"crossref","DOI":"10.1021\/acs.oprd.3c00084","article-title":"Approaches and considerations for the investigation and synthesis of N-nitrosamine drug substance-related impurities (NDSRIs)","author":"Ashworth","year":"2023","journal-title":"Org. Process Res. Dev."},{"issue":"20","key":"10.1016\/j.jpba.2023.115861_bib27","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1021\/ja01074a028","article-title":"Structural studies by nuclear magnetic resonance. IX. Configurations and conformations of N-nitrosamines","volume":"86","author":"Karabatsos","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2023.115861_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27154749","article-title":"NMR assignments of six asymmetrical N-nitrosamine isomers determined in an active pharmaceutical ingredient by DFT calculations","author":"Guan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2023.115861_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2022.100037","article-title":"An improved analytical method for quantitation of nitrosamine impurities in ophthalmic solutions using liquid chromatography with tandem mass spectrometry","volume":"2","author":"Malihi","year":"2022","journal-title":"J. Chromatogr. Open"},{"issue":"9","key":"10.1016\/j.jpba.2023.115861_bib30","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3155\/1047-3289.59.9.1032","article-title":"Estimating precision using duplicate measurements","volume":"59","author":"Hyslop","year":"2009","journal-title":"J. Air Waste Manag. Assoc."},{"issue":"9","key":"10.1016\/j.jpba.2023.115861_bib31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","article-title":"Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water","volume":"24","author":"Ashworth","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2023.115861_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121740","article-title":"Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite","volume":"620","author":"Schlingemann","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.jpba.2023.115861_bib33","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/pr10112428","article-title":"Assessment of a diverse array of nitrite scavengers in solution and solid state: a study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives","volume":"10","author":"Hom\u0161ak","year":"2022","journal-title":"Processes"},{"issue":"12","key":"10.1016\/j.jpba.2023.115861_bib34","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","article-title":"Inhibition of N-nitrosamine formation in drug products: a model study","volume":"110","author":"Nanda","year":"2021","journal-title":"J. Pharm. Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:34:03Z","timestamp":1760002443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523006301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"alternative-id":["S0731708523006301"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115861","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive UHPLC\u2013MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115861"}}